Esperion Q2 revenue $82.4M (+12% Y/Y); first operating income of $15M; expects sustainable profitability Q1 2026

Esperion Therapeutics, Inc.

2025-Q2 EPS reported -$0.27 revenue$147,380,000

U.S. net product revenue $40.3M, +42% Y/Y; total prescriptions up 10% sequential.
Net loss per share $0.02 vs $0.33 loss a year ago; operating income from ongoing business $15M.
Reached settlements with three ANDA filers to block generic NEXLETOL until 2040.
Royalty revenue from European partner up 30% sequentially to $13.6M; Japan approval on track for H2 2025.
Reiterated FY2025 opex $215-235M; cash $86.1M; shares outstanding ~200.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.